Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. - Wikidata - awgldk - TriplyDB

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q38241171

about

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.DPP-4 inhibitors: focus on safety.Albiglutide: a review of its use in patients with type 2 diabetes mellitus.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Controlled release of biologics for the treatment of type 2 diabetes.Half-life extended biotherapeutics.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.Albiglutide: a unique GLP-1 receptor agonist.Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.The safety of albiglutide for the treatment of type 2 diabetes.Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Incretin manipulation in diabetes management.Albiglutide-induced pancreatitis.A streamlined cloning workflow minimising the time-to-strain pipeline for Pichia pastoris.No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.

P2860

Q26799389-74A0B1A2-DB19-45EC-8614-E5DF7AC6A438 Q31082841-8C4A3129-FB02-4E31-B658-A9B0CDEDB135 Q36073461-08194E99-9838-4A21-89BB-0501BD3E51FB Q37729181-35256CA6-AEAB-48F4-9783-1DBA03B72726 Q38285608-C07EA3B0-A5E6-4CD1-A225-B21BED9305C8 Q38380559-53192D08-FDA0-4890-98D3-EF2E4B0FB1DC Q38542098-0CCB9FD9-1A7E-439B-BEC3-E61358BED41C Q38602769-8A531AB5-DF3B-4CD8-AE0A-69EB0C843DD3 Q38665753-CBA6FBBF-8956-43F1-9513-0C6FE9DB9432 Q38770067-47406E0C-4A05-48D9-9D35-33FC8EA2B745 Q38838461-B13A671E-E824-47CC-AEBB-882CB5FF6816 Q38884947-8B983682-0F61-4DA6-AB85-EF10E17DA683 Q38966029-25F226FB-61AA-4AA0-A824-493386E05B7A Q39041615-CE49A04B-BCAE-4C8F-9683-8AE9A3883646 Q39415439-699E631D-28E3-451D-923E-32628EEF3CA9 Q40745963-C21396F3-91A7-45E8-9D44-012216C9756B Q41906284-B48E4657-1443-47FB-8650-E650503A2E24 Q42365383-3A7A58FA-2DAF-4FC9-8BCA-EFB6F38F9386 Q47137573-15195CBF-B8DA-4915-B6AB-0C961A5DE4C4 Q48345845-7A1385C9-9ACE-4C2D-B6B1-84427A6E92F4 Q52663655-D574F2F3-C430-42B1-90DA-9CC4BE5240B7

P2860

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q38241171

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

@en

type

label

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

@en

prefLabel

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

@en

P1433

Q38241171-60319F88-5EF9-440A-9C33-9D9831B7E716

P1476

Q38241171-ECD0D99F-A44C-4569-A6B7-3F4F85239E66

P2093

Q38241171-0C631A22-D98A-4CC5-AD70-E2BF4CD2B6B3

Q38241171-7CE01F6E-532B-44BE-A820-10255AB8726F

P2860

Q38241171-0625E4E6-02ED-49FC-AED8-73FE452EECF6

Q38241171-2FA5CBBE-DAD3-4D8E-A74D-6DF9C33A4434

Q38241171-3D83F271-54BC-487A-8B2F-6C4BEA3E624D

Q38241171-3D98125B-468D-4335-B435-023D25157E35

Q38241171-61913AD5-81C3-480D-8123-208000964B0C

Q38241171-8CAAF9FC-FE5D-4AAE-BB5A-8FC5867A5E07

Q38241171-9742A049-7C00-4C13-B9D6-B406F4B94640

Q38241171-9C62D476-6066-42DA-8BDA-C5F2DB84C120

Q38241171-9D3EACE0-9D0C-4E3E-B4F2-7D2DD40F421A

Q38241171-BA9A21E7-5834-4CA9-8B7C-987CDC90D321

P304

Q38241171-B117FC8E-637A-4F7E-BE3C-D1F29B6601B8

P31

Q38241171-D3370F2A-3858-4FE9-B0E2-7ADABAE331C7

P356

Q38241171-372FF9B6-0EB2-4654-A693-39493A13629B

P407

Q38241171-A5F9165E-7631-4D10-84F7-A2C5EF1ED222

P433

Q38241171-CD24FE2C-62B2-4247-A017-C9BD86125970

P478

Q38241171-5E36ECAF-AED9-4E12-A91B-0F6F8CDDA28E

P577

Q38241171-36A8E220-5A86-47D3-9C09-770A4997A338

P698

Q38241171-1C997553-14A9-48BA-9237-6BB279E3E3F3

P921

Q38241171-DA49CF0E-BA27-435C-8921-D261C650B78D

P356

1060028014545807

P1433

Annals of Pharmacotherapy

P1476

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

@en

P2093

Jennifer M Trujillo

http://www.w3.org/2001/XMLSchema#string

Wesley Nuffer

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

Syntaxin-3 regulates newcomer insulin granule exocytosis and compound fusion in pancreatic beta cells.

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

P304

1494-1501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028014545807

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25136065

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes